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ABSTRACT
Introduction: Neutrophil elastase activity in sputum can identify patients at high risk of airway infection
and exacerbations in bronchiectasis. Application of this biomarker in clinical practice is limited, because
no point-of-care test is available. We tested whether a novel semi-quantitative lateral flow device
(neutrophil elastase airway test stick – NEATstik®) can stratify bronchiectasis patients according to severity,
airway infection and exacerbation risk.
Methods: Sputum samples from 124 patients with stable bronchiectasis enrolled in the UK and Spain were
tested using the NEATstik®, which scores neutrophil elastase concentration from 0 (<8 µg·mL−1 elastase
activity) to 10 (maximum detectable neutrophil elastase activity). High neutrophil elastase activity was
regarded as a NEATstik® grade >6. Severity of disease, airway infection from sputum culture and exacerbations
over the 12 months were recorded. An independent validation was conducted in 50 patients from Milan, Italy.
Measurements and main results: Patients had a median age of 69 years and forced expiratory volume in
1 s (FEV1) 69%. High neutrophil elastase activity was associated with worse bronchiectasis severity using
the bronchiectasis severity index (p=0.0007) and FEV1 (p=0.02). A high NEATstik® grade was associated
with a significant increase in exacerbation frequency, incident rate ratio 2.75 (95% CI 1.63–4.64, p<0.001).
The median time to next exacerbation for patients with a NEATstik® grade >6 was 103 days compared to
278 days. The hazard ratio was 2.59 (95% CI 1.71–3.94, p<0.001). Results were confirmed in the
independent validation cohort.
Conclusions: A novel lateral flow device provides assessment of neutrophil elastase activity from sputum
in minutes and identifies patients at increasing risk of airway infection and future exacerbations.
This article has supplementary material available from erj.ersjournals.com
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ORIGINAL ARTICLE
BRONCHIECTASIS
Introduction
Bronchiectasis is a complex clinical syndrome with a wide spectrum of underlying causes [1]. The
outcome of bronchiectasis can be unpredictable [2]. Although there are prognostic scores to identify
patients at higher risk of mortality, these have limitations such as the inclusion of fixed variables such as
age [2–4]. Airway infection is one of the most important “treatable traits” in bronchiectasis because
chronic infection with Pseudomonas aeruginosa is linked to a significant increased risk of future mortality,
hospital admissions and worse quality of life [5–7]. Infection with other pathogens also provokes airway
neutrophilic inflammation and a higher risk of future exacerbations, particularly if bacterial loads are
high [8]. Alongside airway infection, exacerbations are critical events in bronchiectasis as they are
associated with a significant decrement in quality of life and contribute to disease progression [9, 10].
For this reason, the majority of therapies for bronchiectasis recommended by the European Respiratory
Society (ERS) guidelines either target the suppression of airway infection, such as long-term macrolides or
inhaled antibiotics, or aim to reduce exacerbation frequency [11, 12].
A biomarker that could identify patients in real time that are at risk of future exacerbations or have active
airway infection would help to identify patients in need for intensified treatment.
Neutrophil elastase activity is a leading candidate for a bronchiectasis biomarker [13]. The relationship
between sputum neutrophil elastase activity and airway infection has been known for more than two
decades and studies demonstrate that neutrophil elastase may directly impact on bronchiectasis disease
progression through effects of ciliated epithelium, mucus production, emphysema development and
inactivation of the immune response [14–16]. A systematic review of clinical studies in bronchiectasis
identified 31 studies and found that higher neutrophil elastase activity in sputum was associated with
sputum colour, P. aeruginosa infection, airway bacterial load, disease severity, forced expiratory volume in
1 s (FEV1) symptoms and long-term risk of exacerbations and lung function decline [16].
Therefore, neutrophil elastase has been tested and validated as a biomarker across multiple studies [13, 16–18].
However, it has not been implemented into clinical practice, in part due to the difficulty of standardising
sputum processing and performing ELISA or chromogenic assays in clinical laboratories. A point-of-care
lateral flow device that could evaluate neutrophil elastase in minutes would overcome these limitations and
might help to stratify patients in terms of disease severity and future risk.
In this study we tested the predictive value of a commercially available point-of-care neutrophil elastase
assay (NEATstik®) to predict clinically relevant outcomes in patients with bronchiectasis.
Methods
Patients were enrolled while in a stable phase of their disease from specialist bronchiectasis clinics in
Ninewells Hospital (Dundee, UK) and Hospital Sant Pau (Barcelona, Spain) from 2016 to 2017. The
inclusion criteria were high-resolution computed tomography confirmed bronchiectasis, the clinical
syndrome of bronchiectasis defined by cough, sputum production and/or recurrent respiratory tract
infections, and the ability to produce a sputum sample spontaneously at the study visit. Exclusion criteria
were known cystic fibrosis, traction bronchiectasis due to interstitial lung disease, age <18 years and
inability to give informed consent to participate. The study was approved by the local research ethics
committees.
Patients and clinical outcomes
Following informed consent, we collected information about demographics, clinical characteristics, disease
burden, previous microbiology and current treatments. Sputum samples were sent for bacterial culture and
computed tomography scans were scored using the modified Reiff scale [2]. Patients underwent spirometry
according to American Thoracic Society/ERS guidelines. Quality of life was evaluated using the quality of
life bronchiectasis respiratory symptoms score. The bronchiectasis severity index was calculated as
previously described [2]. Data were collated in the EMBARC case report form including sputum colour
measured using the Murray colour chart [19]. Chronic infection was defined as isolation of the same
pathogen on two or more occasions ⩾3 months apart while clinically stable over 1 year.
Sputum processing and neutrophil elastase measurement
Neutrophil elastase was measured using two methods: a validated activity-based immunoassay and the
point-of-care “NEATstik®” test. For immunoassay, spontaneously expectorated samples were diluted with
8× volume phosphate buffered saline and centrifuged at 3000×g for 15 min and the supernatant carefully
removed, as previously described [13]. Dithiothreitol was not used. Samples were diluted and neutrophil
elastase activity measured according to the manufacturer’s instructions. For the NEATstik® method,
spontaneously expectorated sputum samples were diluted immediately 10× in buffer provided in the kit
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and inverted 10 times. The diluted sample was then added to the NEATstik® lateral flow device. The test
consists of a control line and a test line. According to the manufacturer’s instructions the intensity of the
test line corresponds to the neutrophil elastase concentration on a 10-point scale (figure 1), and a positive
test corresponds to an approximate concentration of 8 µg·mL−1. A video showing the testing procedure is
included in the supplementary material.
Exacerbation study
A subset of patients were asked to contact the study site when they experienced an exacerbation and to
provide a spontaneous sputum sample. In this convenience sample, patients were reviewed by a clinician
and exacerbation defined according to the British Thoracic Society definition [20]. Bacterial exacerbations
were defined by the presence of a cultured pathogen and viral exacerbations defined by the presence of a
positive PCR.
Validation
The reliability and reproducibility of the NEATstik® scoring system was tested. Each processed sputum
sample was scored by two blinded independent observers. Observer agreement was evaluated using Bland–
Altman plots, linear regression and the area under the receiver operator characteristic curve. Image
analysis was conducted to provide a third validation and proof of concept that digital validation of
photographs taken on a mobile phone camera could be used for future development of an app or similar
assessment device. A subset of 50 images were photographed, converted to an 8-bit greyscale image and
adjusted to obtain a consistent background and control line intensity. Mean pixel intensity of the
NEATstik® test band was quantified in FIJI (ImageJ; opensource software, National Institutes of Health,
Bethesda, MD, USA).
Additionally, agreement between the NEATstik® assay and the immunoassay was tested.
Validation cohort
An independent validation study was performed at a specialist bronchiectasis clinic (Policlinico Hospital,
Milan, Italy). The NEATstik® assay was performed on fresh sputum samples at the point of care in 50
patients; 25 with chronic bacterial infection and 25 without chronic infection. Clinical data were collected,
but no follow-up data were collected in this cohort. NEATstik® results were verified by two observers.
Statistical analysis
Analysis was performed double-blind, with staff performing the scoring of the NEATstik® grade blinded to
patient characteristics and the staff who obtained sputum samples and collated clinical data blinded to the
results of the NEATstik® test until the end of the study. For correlating neutrophil elastase activity with
clinical parameters and long-term outcomes, two cut-offs were used. First, a comparison between samples
testing positive (any grade 1–10) versus negative; and second, a comparison between the highest
NEATstik® grades (>6 versus ⩽6) selected a priori based on the correlation with the immunoassay levels of
neutrophil elastase.
Analysis was performed using SPSS 22.0. Statistical differences among continuous variables were analysed
using t-test and ANOVA or the appropriate nonparametrical test. Frequency of exacerbations and hospital
admissions during the study were analysed using a negative binomial model with follow-up time as an
offset. Time to first exacerbation was evaluated using Kaplan–Meier survival analysis. We defined statistical
significance as a two-tailed p<0.05.
Results
Patient characteristics
124 patients were included in the study. The patient characteristics summarised in table 1 were consistent
with previously reported characteristics of European bronchiectasis populations.
Accuracy and reproducibility of neutrophil elastase measurement
There was a clear and statistically significant correlation between neutrophil elastase activity measured
using the immunoassay and the NEATstik® result (Spearman correlation r=0.73, p<0.001).
FIGURE 1 NEATstik® scoring system.
A value of 0–10 is awarded, based
on the intensity of the band.
10876543210 9
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The two blinded observers showed a high level of agreement (r=0.93, p<0.001). There was a strong
agreement between both observers and quantification of the test line by image analysis of digital
photographs (n=50; observer 1 r=0.81, p<0.001 and observer 2 r=0.91, p<0.001). 21 sputum samples had
no detectable neutrophil elastase activity (grade 0). There was agreement on 20 (95.2%) out of 21 negative
samples between observers (one awarded grade 1 for a single sample that the original observer rated as
negative). Based on the low number of negative results, we set a cut-off value of >6 as a positive or
“high-risk” test. The κ statistic for agreement using this cut-off was 0.82 (0.73–0.91). The Bland–Altman
plot is shown in supplementary figure E1. We conclude that scoring can be performed with a high degree
of reproducibility.
Relationship between point-of-care neutrophil elastase assay and cross-sectional severity of
disease
Compared to patients without chronic infection, patients with P. aeruginosa had significantly higher
neutrophil elastase activity (figure 2a), as did patients with other chronic infections (p=0.004). Of those
without detectable neutrophil elastase activity, only one had chronic infection. The sensitivity and
specificity for detection of chronic infection were 71.9% and 55.1%, respectively, for a NEATstik® grade >6,
TABLE 1 Characteristics of the study population
Demographics
Age years 69 (62–78)
Female 71 (57.3)
BMI kg·m−2 25.6 (22.4–29.8)
Ex-smokers 50 (40.3)
Current smokers 9 (7.3)
Aetiology
Idiopathic 64 (51.6)
Post-infective 11 (8.9)
COPD 9 (7.3)
Post-TB 7 (5.6)
Rheumatoid arthritis 7 (5.6)
Inflammatory bowel disease 6 (4.8)
ABPA 3 (2.4)
Asthma 3 (2.4)
Immunodeficiency 3 (2.4)
Other# 11 (8.9)
Disease severity
BSI score 7 (5–11)
BSI score risk class
Mild 31 (25)
Moderate 44 (35.5)
Severe 49 (39.5)
Clinical status
Sputum volume mL·day−1 15 (5–30)
MRC dyspnoea score 2 (1–2)
Exacerbations in the previous year 2 (1–4)
At least one hospitalisation in the previous year 37 (29.8)
Functional status
FEV1 % predicted 67.9 (50.9–81.5)
Microbiology
P. aeruginosa chronic infection 35 (28.2)
Negative sputum culture 62 (50.0)
Treatment
Long-term macrolide 51 (41.1)
Inhaled antibiotic 18 (14.5)
Quality of life
Quality of life bronchiectasis questionnaire respiratory symptom score 59.3 (46.8–77.8)
Data are presented as median (interquartile range) or n (%). BMI: body mass index; COPD: chronic
obstructive pulmonary disease; TB: tuberculosis; ABPA: allergic bronchopulmonary aspergillosis; BSI:
bronchiectasis severity index; MRC: Medical Research Council; FEV1: forced expiratory volume in 1 s;
P. aeruginosa: Pseudomonas aeruginosa. #: included α1-antitrypsin deficiency, obstruction, primary ciliary
dyskinesia and tracheobronchomegaly.
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and 98.3% and 31.3% for positive versus negative NEATstik® results. The corresponding sensitivity and
specificity for detecting P. aeruginosa infection were 100% and 23.6%, respectively.
Figure 2b shows the relationship between neutrophil elastase and the bronchiectasis severity index (BSI).
Patients with more severe bronchiectasis had higher neutrophil elastase activity (p<0.001). The linear
correlation between neutrophil elastase grade and BSI was r=0.31 (0.14–0.47, p<0.001). Neutrophil elastase
grade was also correlated with Medical Research Council MRC dyspnoea score (r=0.25, 95% CI 0.07–0.42;
p=0.008), FEV1 (r=−0.33, 95% CI −0.49–−0.16; p<0.001) and the quality-of-life bronchiectasis
questionnaire respiratory symptom score (r=−0.37, 95% CI −0.56–−0.15; p=0.002). Correlations, including
those with bacterial infection, BSI and FEV1 were all consistent when evaluated individually in both the
Spanish and UK cohorts.
Classifying NEATstik® results as simply positive and negative showed relationships with clinical
parameters, with positive tests being associated with a higher BSI score, lower FEV1 and the presence of
airway infection (supplementary figure E2).
Predictive value for future exacerbations
A high NEATstik® grade (>6) was predictive of future exacerbations. The median time to next exacerbation
for patients with a NEATstik® grade >6 was 103 days, compared to 278 days for those with lower
NEATstik® grades. The Kaplan–Meier survival curve is shown in figure 3a. The hazard ratio was
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FIGURE 2 The relationship between the NEATstik® grade, airway infection and severity of disease. a) Airway infection, b) bronchiectasis severity
index, c) forced expiratory volume in 1 s (FEV1) groups. Data are shown as mean±SEM. Coloured error bars are to improve visualisation rather than
having any significance.
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FIGURE 3 Time to first exacerbation according to baseline NEATstik® neutrophil elastase result. a) High (NEATstik® grade >6) versus low scores;
b) positive (any grade >0) versus negative result.
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2.59 (95% CI 1.71–3.94, p<0.001). Similarly, comparing positive versus negative results, there was a
statistically significant difference in time to the next exacerbation event. The median time was 135 days
for patients with a positive test versus 320 days for patients with a negative test. The hazard ratio was
2.15 (95% CI 1.32–3.51, p=0.01).
A high NEATstik® level was associated with a significant increase in exacerbation frequency during
follow-up with an incident rate ratio of 2.75 (95% CI 1.63–4.64, p<0.001) from the negative binomial
model. There was consistency between the UK and Spain cohorts and in terms of prediction of
exacerbations (supplementary figure E3).
Severe exacerbations requiring hospitalisation were infrequent during this study, occurring in 20 patients
(mean±SD 0.29±0.75 per year). 19 out of 20 patients requiring hospitalisation had an elevated NEATstik®
grade >6. The single patient with a level <6 had a negative NEATstik®. The calculated risk ratio for a
NEATstik® grade >6 was 12.8 (95% CI 1.77–91.9, p<0.001). The equivalent for positive versus negative
NEATstik® results was 3.87 (95% CI 0.55–27.4, p=0.2). It should be noted that 12 out of 20 patients
requiring hospitalisation had chronic P. aeruginosa infection, which we had already observed to be
associated with high neutrophil elastase activity in sputum.
Neutrophil elastase activity during exacerbations
42 patients attended for visits during protocol-defined exacerbations. Details of sputum culture results at
exacerbation are shown in the supplementary material. As previously observed with neutrophil elastase
ELISA [21], changes in neutrophil elastase at exacerbation were heterogeneous and NEATstik® was not
useful in differentiating stable state from exacerbation.
Bacterial exacerbations had higher mean NEATstik® grades, as shown in figure 4. Comparisons with both
viral and negative exacerbations were statistically significant (p=0.005 and p=0.001, respectively). The
small numbers did not allow a meaningful comparison between viral and “negative” exacerbations.
Independent validation
The characteristics of the validation cohort are shown in supplementary table E2. The relationship between
NEATstik® grade and chronic infection was confirmed in this cohort (figure 5a and b). There was a strong
agreement between two independent observers for NEATstik® grade, with the correlation for two
physicians (r=0.91, 95% CI 0.84–0.95; p<0.001) and for scoring performed by a nurse (r=0.91, 95% CI
0.84–0.95; p<0.001) and by a physiotherapist (r=0.92, 95% CI 0.86–0.95; p<0.001) showing similar
reproducibility. NEATstik® result was not significantly correlated with the sputum colour chart (r=0.18,
p=0.2) but was correlated with sputum volume (r=0.39, 95% CI 0.10–0.62; p=0.01). Sputum colour was
not associated with BSI (p=0.06) or chronic infection (p=0.1).
Discussion
To the best of the authors’ knowledge, this is the first description of a rapid point-of-care test that can
identify the presence of airway infection and the risk of future exacerbations in patients with
bronchiectasis. The test is semi-quantitative and shows a good correlation with neutrophil elastase activity
measured by immunoassay. Neutrophil elastase activity is an established biomarker of bronchiectasis as
FIGURE 4 Neutrophil elastase
NEATstik® results at exacerbation in
42 patients: bacterial exacerbations
(n=25), viral exacerbations (n=8) and
exacerbations where both sputum
culture and viral PCR were
negative (n=7). Data are presented
as mean±SEM.
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well as being associated with risk of exacerbations, airway infection status and lung function decline in
other conditions such as cystic fibrosis [16]. Implementation of sputum biomarkers into clinical practice
are limited by the requirement to process sputum via centrifugation and the design of traditional assays
for neutrophil elastase, which are typically based on the cleavage of chromogenic substrates. Therefore,
the NEATstik® method has a number of advantages over existing methods of neutrophil elastase
quantification. The procedure requires only a sample container, a weighing balance and the NEATstik®
device and a result can be obtained within minutes. It is feasible to perform this test in a clinic setting or
for a patient to perform the test at home.
Neutrophil elastase is released from azurophilic granules of neutrophils during degranulation or neutrophil
extracellular trap formation [22]. The strongest driver of neutrophil recruitment to the airway and
subsequent degranulation is bacterial infection [8]. Several studies have shown that patients with
P. aeruginosa infection have high levels of neutrophil elastase activity [8, 13, 17, 18]. Previous work shows
a strong relationship between neutrophil elastase activity and bacterial load, but for pragmatic reasons we
did not perform quantitative bacteriology in this study. Patients with more severe bronchiectasis had
higher neutrophil elastase activity in this study, as previously reported [13]. The BSI is a composite score
that includes age, body mass index, MRC dyspnoea score, radiological bronchiectasis, exacerbations,
hospitalisations, FEV1 and chronic infection. We show here that the relationship between neutrophil
elastase activity and severity is driven by worse symptoms of breathlessness, more exacerbations, worse
lung function and more chronic infection in patients with higher levels of neutrophil elastase.
We identified very few samples (21 out of 124 in stable patients) that were truly negative using the
NEATstik® assay. For this reason, the semi-quantitative scoring may be most useful in clinical practice,
since a positive/negative approach may be too sensitive and insufficiently specific. Conversely, the 100%
sensitivity we observed for P. aeruginosa infection suggests that, if validated in further independent
cohorts, a negative test could be used to effectively exclude the presence of P. aeruginosa infection without
requiring culture. We found that the semi-quantitative grading could be performed reliably and
reproducibly between independent observers.
Exacerbations are key drivers of disease progression in bronchiectasis. Elevated neutrophil elastase predicted
a shorter time to the next exacerbation and a higher frequency of exacerbations during follow-up. The
magnitude of this effect with the NEATstik® method was similar to that previously observed with an
immunoassay in an independent cohort [13]. The prediction of exacerbations to guide preventative therapy
is a key unmet need in the management of bronchiectasis patients. The ERS guidelines recommend
long-term macrolides, long-term inhaled antibiotics and some mucoactive therapies to patients at risk of
future exacerbations, but at present the only method available to predict future exacerbations is the history
of previous exacerbations [9]. While these are strongly correlated, recent experience suggests that this
method is not always reliable. In the RESPIRE trials of inhaled dry powder ciprofloxacin, the inclusion
criteria required at least two exacerbations in the previous year [23–25]. The subsequent rates of
exacerbation of 0.6–1 per year in the placebo groups of these trials suggest a failure to enrich for patients at
high risk of exacerbation events. Therefore, a point-of-care test that can identify patients at risk would be
useful in clinical practice to guide therapy and to enrich clinical trials.
We performed a pilot study of 42 exacerbations to investigate if different exacerbation types had different
levels of neutrophil elastase. We found a clear association between elevated neutrophil elastase positive
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bacterial culture at exacerbation. It is important to note that negative NEATstik® tests were observed at
exacerbation, confirming that neutrophil elastase cannot be used to diagnose exacerbation, since there
appear to be phenotypes of exacerbation that are not associated with elevated neutrophilic inflammation
[13]. Nevertheless, our initial observation would suggest the future potential to guide antibiotic treatment
of exacerbations based on the NEATstik® result.
Our study has important limitations. The sample size was sufficient to demonstrate statistically significant
differences between the groups, but given the heterogeneity of bronchiectasis it would be important to
investigate the NEATstik® assay in a larger cohort of patients. Our study was limited to 12 months of
follow-up and there were relatively few severe exacerbations on which to base any strong conclusions
regarding this end-point. As the participating hospitals are tertiary referral centres, the study included a
high proportion of patients with severe bronchiectasis, and therefore care should be taken if extrapolating
results to a milder population. Our independent validation cohort included only 50 patients and was
designed to validate the association with airway infection; it was not powered to test the association with
exacerbations. Further large studies are still needed. An important limitation of our respiratory infection
data is the reliance on traditional culture methods. Studies are increasingly using more sensitive methods
such as quantitative PCR or sequencing of the airway microbiome to define airway infection [26]. These
methods are not yet implemented in clinical practice and so we regard culture as an appropriate gold
standard for our analysis, albeit one with important limitations. Despite these limitations, our study has
many strengths, including the extensive validation of the assay, the multicentre design with consistent
results between Spain, Italy and the UK and the comprehensive clinical data recorded.
In summary, a simple point-of-care semi-quantitative neutrophil elastase assay can identify bronchiectasis
patients with airway infection and patients at high risk of exacerbations over the subsequent 12 months.
Future studies should evaluate whether implementation of such an assay in clinical practice or clinical
trials can be used to improve risk stratification or therapeutic decision making.
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